Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.56 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.56 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14157232 | 0.99 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL3652558 | 0.92 | SMN1; SMN2 (0.61) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| Hydrochloric Acid SCHEMBL7101636 | 0.91 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL15140566 | 0.90 | SMN1; SMN2 (0.72) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL618588 | 0.89 | SMN1; SMN2 (0.71) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| Hydrochloric Acid SCHEMBL23301123 | 0.88 | SMN1; SMN2 (0.69) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL458148 | 0.88 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL21553751 | 0.88 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL8553423 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL6823133 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118147098-B | Leucine dehydrogenase mutant and application thereof in chiral nitrogen heterocyclic amine synthesis | 江南大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-118147098-A | Leucine amine dehydrogenase mutant and application thereof in chiral nitrogen heterocyclic amine synthesis | 江南大学 | 2024-06-07 | — | — | CN | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| EP-0625509-B1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LTD (GB) | 1997-07-30 | — | — | EP | disclosed |
| US-5521199-A | TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0625509-A1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | SMN1; SMN2 4274/4885CYP2C19 2221/4885NPC1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.